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Abstract
Background: The IGF system is recognised to be important for fetal growth. We previously described increased Insulin-like
growth factor binding protein (IGFBP)-2 cord serum concentrations in intra-uterine growth retardation (IUGR) compared
with appropriate for gestational age (AGA) newborns, and a positive relationship of IGFBP-2 with Interleukin (IL)-6. The role
of cortisol in the fetus at birth is largely unknown, and interactions among peptides are their real effect on birth size is
unknown. Furthermore, almost all studies have previously assayed peptides in serum several years after birth, and follow-up
data from pregnancy are always lacking. This study aimed at establishing and clarifying the effect of cord serum insulin, IGF-
II, IGFBP-2, cortisol and IL-6 concentrations on birth length and weight.
Methods: 23 IUGR and 37 AGA subjects were followed up from the beginning of pregnancy, and were of comparable
gestational age. Insulin, IGF-II, IGFBP-2, cortisol and IL-6 concentrations were assayed in cord serum at birth, and a multiple
regression model was designed and applied to assess which were the significant biochemical determinants of birth size.
Results: Insulin, cortisol, and IL-6, showed similar concentrations in IUGR and AGA as previously described, whereas IGF-II
was lower, and IGFBP-2 increased in IUGR compared with AGA. IGF-II serum concentration was found to have a significant
positive effect on both birth length (r:
:0.546; p: 0.001) and weight (r:0.679; p: 0.0001). IGFBP-2 had a near significant negative
effect on both birth weight (r:20.342; p: 0.05) and length (r:20.372; p:0.03).
Conclusion: IGF-II cord serum concentration was shown to have a significant positive effect on both birth length and
weight, whereas IGFBP-2 had a significant negative effect. Insulin, cortisol, and IL-6 cord serum concentrations had no
significant effect on birth size.
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Introduction
Fetal growth is driven mainly by the IGF system as experiments
in knockout mice have shown [1,2]. IGF-II and the type I IGF
receptor are thought to be the most important for fetal growth [3,4].
We described increased IGFBP-2 cord serum concentrations in
IUGR compared with appropriate for gestational age (AGA)
newborns, and a positive relationship of serum IL-6 with IGFBP-2
[5], although IL-6 concentration did not show any changes in the
two conditions. We described instead increased IL-6 mRNA and
protein concentrations in placental lysates from IUGR [5], and
our recent evidence suggested a negative effect, although not a
major effect, of IL-6 placental concentration on birth size (our
unpublished data).
Very little data has been published on the fetus to date.
Certainly it is of interest to consider the described molecular
mechanisms by which IL-6 can induce insulin-resistance [6,7].
Furthermore, animal and human studies showed a marked
activation of the hypothalamic-pituitary-adrenal axis by IL-6
infusion [8–10].
We previously described similar cortisol and insulin concentra-
tions in cord serum of newborns, both IUGR, and AGA.
The role of cortisol in the fetus at birth is largely unknown.
Interestingly, Cianfarani et al. reported a positive correlation of
cortisol serum concentrations with IGFBP-1, and a negative
correlation with IGF-I and length gain in the first 3 months of life,
in normal neonates [11]. The same authors subsequently reported
higher cortisol serum concentrations at the age of nine years in
IUGR subjects who failed to catch-up with growth, compared with
those who caught-up, and a negative relationship with birth weight.
Itwasalsosuggested that theincreased cortisolserum concentrations
reduced IGFBP-3 proteolysis reducing IGF bioavailability [12].
IUGR and appropriate for gestational age (AGA) newborns show
differences but are subjected overall to the same biological laws.
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e29562We followed-up a unique series of newborns, both IUGR and
AGA, from pregnancy to birth [5,6], and assessed in cord serum
which peptides had a significant effect on birth length and weight,
among insulin, IGF-II, IGFBP-2, cortisol and IL-6.
Materials and Methods
Subjects
Twenty-three IUGR (13M, 10F) and 37 AGA (18M, 19F),
births of comparable gestational age (34.860.6 vs. 36.160.4
weeks, respectively, n.s.) were followed during pregnancy. All
pregnancies were dated correctly by ultrasound during the first
trimester of gestation.
AGA newborns were defined on the basis of a normal birth
weight (,80th and .10th centiles) with respect to the Italian
standards [13], a normal pregnancy and the absence of maternal
risk factors.
The diagnosis of IUGR was made within the 32nd week of
gestation and was ascribed to a probable placental cause after
excluding other causes as infections, chromosomal abnormalities,
genetic syndromes, maternal malnutrition, substance abuse
including smoking, gross placental abnormalities and multiple
fetuses. No cases with hypertension, gestational diabetes or
reduced amount of amniotic fluid were included in the study.
Mothers were all normal-weight subjects and data on parity, were
collected also.
The IUGR pregnancies were diagnosed by ultrasound accord-
ing to the following criteria: abdominal circumference ,10th
centile and/or shift of fetal growth with a reduction of abdominal
circumference with respect to the measure taken during the 20th
week of gestation. In IUGR subjects, doppler velocimetry was
altered in almost all cases in the placenta and/or fetus site. All
neonates, both IUGR and controls, were delivered by elective
caesarean section (CS).
The causes of preterm birth (,38 weeks of gestation) in the
AGA newborns were: intra-hepatic cholestasis in a woman who
had underwent a previous CS, premature rupture of membranes
with breech presentation and delivery within 4 hours with no signs
of infection. Elective CS in these subjects was performed because
of refusal of vaginal delivery for psychological reasons, or because
of a previous CS.
We could obtain a complete data-set on which this study was
performed in 34 subjects. The main clinical features of these
newborns are shown in Table 1.
Data collection and measuring techniques
Length (Lt) and weight (Wt) at birth was measured by trained
midwives at our hospital using exact measuring equipment for
length measurements. At birth auxological data were plotted
according on to the Italian standards [13].
At birth the following information was also collected: age of the
mother, weight at birth of both parents, body mass index (BMI) of
the mother before pregnancy, previous gynaecological history,
medical history during pregnancy, fetal biophysical data (exact
duration of pregnancy, growth trend), clinical data at delivery
(indication for CS, neonatal data as sex, weight, length, head
circumference, APGAR score, acid-base equilibrium, perinatal
data), weight and macroscopic aspect of the placenta.
Collection of biological material
Umbilical cord serum from IUGR and AGA births were
collected at birth and treated as previously described [5]. The
blood was delivered to the laboratory within 20 minutes,
centrifuged (2000 g/min for 10 minutes at 4uC) and the sera
aliquoted and stored at 280uC until assayed.
Cord serum assays
Peptides were assayed as previously described, prior to this study
[5,6].
Briefly, IGF-II was measured using an IRMA method
(Diagnostic System Laboratories, Inc. Webster, Texas, USA).
IGFBP-2 was assayed using a RIA method (Diagnostic System
Laboratories, Inc. Webster, Texas, USA).
Insulin was assayed using a specific IRMA assay (DiaSorin
S.p.A., Saluggia, Italy).
IL-6 was measured using an ultrasensitive ELISA method
(Quantikine HS, R&D Systems, Minneapolis, MN, USA).
Cortisol was assayed using a specific RIA assay (DiaSorin
S.p.A., Saluggia, Italy).
Ethical approval
Informed consent was obtained from the mothers. The study
was approved by the Ethics Committee of the University of Parma
Medical School.
Statistical analysis
Statistical analysis was performed using SPSS 18.0 for Windows
(SPSS, Inc, Chicago, IL).
Table 1. Main clinical features at birth of both IUGR and AGA newborns.
IUGR (13: M6, F7 ) AGA (21: M9, F12 ) p-Value
Gestational age (yr) 35.760.5 36.960.4 n.s.
Mother’s chronological age (yr) 32.061.2 34.260.7 n.s.
Mother’s BMI at beginning of pregnancy (kg/m2) 22.660.9 22.360.7 n.s.
Mother’s birth weight (kg) 3.260.2 3.460.1 n.s.
Father’s birth weight (kg) 3.260.2 3.460.1 n.s.
Parity 1.8660.4 2.2560.2 n.s.
Placental weight (g) 341.7631.6 601.0621.8 0.0001
Birth weight (kg) 1.860.3 2.960.1 0.001
Birth length (cm) 41.161.1 49.960.5 0.0001
Birth head circumference (cm) 29.260.7 34.460.4 0.0001
Data are mean 6 SEM. The comparison between the 2 groups was done using an unpaired T-test.
doi:10.1371/journal.pone.0029562.t001
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all peptide concentrations in placenta could be obtained for 34
subjects.
Results for males and females were combined as in this series we
did not detect any significant difference between the two sexes.
Prior to the study we compared concentrations between cord
serum peptide concentrations to check whether previous reported
differences were confirmed in this population using an unpaired T
test. Results are reported in Table 2, and confirmed our previous
findings [5,6].
The normal distribution of the data was determined using the
Kolmogorov-Smirnov test.
Multiple linear regression analysis was used, with stepwise
eliminations of the independent variables, to study the effect of
individual peptides on parameters of birth size of both IUGR and
AGA newborns, as both populations are subjected to the same
general growth rules, and to obtain acceptable statistical power.
No significant effect of gestational age was found as expected,
considering that gestational ages were similar.
Parity was ruled out also as was similar in the two groups.
We used Bonferroni correction to correct for multiple linear
regression modeling. Statistical significance was set at a p-value
less than 0.007 (p: 0.05/x; x=7).
For the analysis of the variables influencing both length and
weight at birth, the independent variables were insulin, IGF-II,
IGFBP-2, cortisol, and IL-6 concentrations in cord serum at birth.
Results
Determinants of birth length
In the multiple regression model the overall R
2 was 0.570
(p:0.0001).
IGF-II cord serum concentration was shown to have a
significant positive effect on birth length (p: 0.001) (Table 3).
IGFBP-2 cord serum concentration had a negative effect on
birth length (p:0.03) (Table 3).
No significant effect of insulin, cortisol, and IL-6 was shown.
Determinants of birth weight
In the multiple regression model the overall R
2 was 0.461
(p:0.0001).
IGF-II cord serum concentration was shown to have a
significant positive effect on birth weight ( p: 0.0001) (Table 4).
IGFBP-2 cord serum concentration had a negative effect on
birth weight (p:0.05) (Table 4).
Discussion
Among the cord serum peptides analysed, we described IGF-II
and IGFBP-2 as the peptides having the most important effect on
both birth length and weight. In this pilot study, insulin, cortisol,
and IL-6 cord serum concentrations did not seem to have a major
effect on birth size.
Data in the Literature to date, concerning the relationship of IGF-
II with fetal growth arestillcontroversial[14–18].Our IGF-II finding
is in accordance with the experimental evidence in animal models, in
particular, in mouse models [3,19–20]. Recent data have further
proven, from a genetic point of view, the growth-promoting function
of IGF-II during mouse embryogenesis, which has been shown to be
mediated in part by signalling through the insulin receptor [19].
Interestingly, IGF-II has been shown to have also a critical role
for neural and cardiovascular development in zebrafish embryos
[21], and in general distinct functions have been proven during
organogenesis, including the embryonic development of the
kidneys [22].
Our finding is in agreement with previous studies also, in
humans, showing that IGF-II gene polymorphisms are associated
with birth weight and fetal growth, as some gene polymorphisms
through IGF-II gene expression clearly associate with birth weight
SDS [23,24]. However, there are few and controversial data on
the correspondence of gene polymorphisms and IGF-II serum
concentrations [24]. Finally, studies have shown that IGF-II is also
capable of stimulating somatic overgrowth in utero [25].
We previously described increased IGFBP-2 cord serum
concentrations in IUGR compared with AGA newborns, however,
the biological meaning of that finding with respect to other
changes detected in serum in IUGR at that time was unknown, as
well as clear relationships with birth length and/or weight [5].
This pilot study now suggests a major negative effect of IGFBP-
2 on both birth length and weight, altogether a novel and
Table 2. Concentrations of cord serum peptides in IUGR and
AGA at birth.
IUGR AGA p-Value
Insulin (pmol/ml) 55.2613.8 70.364.9 n.s.
IGF-II (ng/ml) 461.9621.6 646.7626.7 0.017
IGFBP-2 (ng/ml) 2685.86430.6 1175.86144.7 0.006
Cortisol (pmol/ml) 295.2633.1 275.9613.8 n.s.
IL-6 (pg/ml) 4.761.8 3.260.5 n.s.
Data are mean 6 SEM. Comparisons between the two groups were done using
an unpaired T-test.
doi:10.1371/journal.pone.0029562.t002
Table 3. Effect of cord serum insulin, IGF-II, IGFBP-2, cortisol,
and IL-6 on birth length.
B Partial Correlation p-VALUE*
Insulin (pmol/ml) 0.126 0.190 0.298
IGF-II(ng/ml) 0.523 0.546 0.001
IGFBP-2(ng/ml) 20.321 20.372 0.030
Cortisol (pmol/ml) 0.068 0.580 0.580
IL-6 (pg/ml) 20.195 20.282 0.118
*p-values were corrected using Bonferroni’s criteria.
doi:10.1371/journal.pone.0029562.t003
Table 4. Effect of cord serum insulin, IGF-II, IGFBP-2, cortisol,
and IL-6 on birth weight.
B Partial Correlation p-VALUE*
Insulin (pmol/ml) 0.171 0.230 0.198
IGF-II (ng/ml) 0.679 0.679 0.0001
IGFBP-2 (ng/ml) 20.307 20.342 0.050
Cortisol (pmol/ml) 0.021 0.029 0.874
IL-6 (pg/ml) 20.210 20.286 0.107
*p-values were corrected using Bonferroni’s criteria.
doi:10.1371/journal.pone.0029562.t004
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IGFBP-2 has been found in fact to be possibly the most useful,
among other peptides of the IGF system, in assessing nutritional
status in preterm neonates during the early postnatal period [26],
and in adults a strong association between low IGFBP-2 levels and
metabolic syndrome has been identified [27]. A recent study has
further shown that during clamp studies, insulin increases IGFBP-
2, and that IGFBP-2 was an independent predictor of insulin
sensitivity. This suggested that this peptide played an important
role in the insulin-IGF cross talk and was thus closely linked to
insulin resistance [28]. Moreover, in obesity, IGFBP-2 was shown
recently to reflect long-term insulin sensitivity [29].
Interestingly, in recent years independent effects of IGFBP-2 on
glucose metabolism have been discovered also [30]. A recent report
inyoung adultsbornsmall forgestational age suggested thatIGFBP-
2 could be a cardiovascular risk marker in later life [31]. However,
these findings in adults are all related to serum concentrations in
later life compared to our subjects, and it is yet unknown whether
cord serum concentrations could anticipate later findings.
Altogether, our findings related to IGF-II and IGFBP-2 still
suggest an important role of insulin, although our analyses
suggested an indirect and not a major effect. Cortisol and IL-6
in the fetus at birth, do not seem to have a major role in
determining birth size, however, the model did not exclude
completely an effect which could also be indirect. Interestingly, our
recent data show a positive effect of insulin placental concentration
on both birth length and weight (unpublished), although the major
effect would be mediated through cortisol placental concentration.
In conclusion, the findings of this pilot study evidenced a
relationship, in particular, of IGF-II and IGFBP-2 cord serum
concentrations with birth size, and also could suggest a possible
relationship of fetal size with insulin sensitivity in later life, as
previous clinical observations have hypothesized [32].
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